Archives

  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • 2021-12
  • 2021-11
  • 2021-10
  • 2021-09
  • 2021-08
  • 2021-07
  • 2021-06
  • 2021-05
  • 2021-04
  • 2021-03
  • 2021-02
  • 2021-01
  • 2020-12
  • 2020-11
  • 2020-10
  • 2020-09
  • 2020-08
  • 2020-07
  • 2020-06
  • 2020-05
  • 2020-04
  • 2020-03
  • 2020-02
  • 2020-01
  • 2019-12
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2019-07
  • 2019-06
  • 2019-05
  • 2019-04
  • 2018-07

    • SLU-PP-332: An ERRα ERRβ ERRγ Agonist for Mitochondrial B...

    2025-12-06

    SLU-PP-332: Catalyzing Mitochondrial Biogenesis and Endurance Through ERRα/β/γ Activation

    Principle Overview: SLU-PP-332 as a Mitochondrial Biogenesis Activator

    SLU-PP-332 (CAS No. 303760-60-3), available from APExBIO, is a cutting-edge synthetic small-molecule peptide analog designed as a potent estrogen-related receptor agonist. Specifically, it targets ERRα, ERRβ, and ERRγ—nuclear receptors that orchestrate mitochondrial biogenesis, cellular respiration, and energy metabolism. By activating these receptors, SLU-PP-332 serves as a cellular respiration regulator and enhances mitochondrial function in skeletal muscle, heart, and brain tissue. Notably, its EC50 values are 98 nM (ERRα), 230 nM (ERRβ), and 430 nM (ERRγ) in vitro, indicating robust potency and selectivity (Mahale et al., 2024).

    Recent research highlights SLU-PP-332 as a next-generation mitochondrial biogenesis activator, mimicking exercise-induced metabolic pathways, promoting fatty acid oxidation, and improving glucose regulation. These properties make it a valuable tool for modeling exercise endurance, metabolic syndrome, and neuroprotection, as well as for investigating anti-aging pathways. For a direct product overview, see SLU-PP-332 at APExBIO.

    Experimental Workflow: Protocol Enhancements with SLU-PP-332

    1. Compound Preparation and Storage

    • Solubility: SLU-PP-332 is readily soluble in DMSO (≥50.8 mg/mL) and ethanol (≥2.39 mg/mL with gentle warming and ultrasonic treatment). It is insoluble in water.
    • Stock Solutions: Prepare fresh aliquots in DMSO or ethanol, store at -20°C, and avoid repeated freeze-thaw cycles. Solutions are not recommended for long-term storage due to potential degradation.
    • Powder Storage: Stable for 3 years at -20°C; for short-term work, keep at 0–4°C for days to weeks.

    2. In Vitro Experimental Setups

    • Cell Lines: C2C12 myotubes, primary skeletal muscle cells, and cardiomyocytes are optimal for probing mitochondrial responses.
    • SLU-PP-332 Dosage: Concentrations ranging from 50 nM to 1 μM are effective for ERR activation. For titration experiments, a slu-pp-332 dosage calculator is recommended. For example, a 250 mcg per day regimen has been explored in preclinical models (see “slu pp 332 dosage of 250mcg per day”).
    • Treatment Duration: Acute (6–24 h) or chronic (up to 7 days) treatments can be applied based on endpoint (e.g., gene expression, oxygen consumption rate).
    • Assays:
      • Monitor mitochondrial biogenesis markers (e.g., PGC-1α, TFAM, NRF1) via RT-qPCR and Western blot.
      • Analyze cellular respiration using Seahorse XF Analyzer (OCR/ECAR).
      • Assess fatty acid oxidation (FAO) and glucose uptake assays.

    3. In Vivo Protocols

    • Administration: Early studies support oral administration due to favorable bioavailability. For dosing, refer to “slu pp 332 dosage chart” and “slu-pp-332 dosage per day pdf.”
    • Endpoints: Endurance testing (treadmill, swimming), glucose tolerance, and lipid profiling are standard for phenotypic outcomes.

    Advanced Applications and Comparative Advantages

    1. Exercise Mimetics and Metabolic Health

    SLU-PP-332 has been shown to mimic exercise-induced physiological adaptations, such as increased energy expenditure and enhanced fatty acid oxidation, leading to reduced fat mass in murine models (Mahale et al., 2024). It drives upregulation of genes like Pdk4 and PGC-1α, central to mitochondrial biogenesis and metabolic flexibility.

    This positions SLU-PP-332 as a pivotal tool for:

    • Modeling human metabolic disorders (obesity, type 2 diabetes, heart failure).
    • Studying neuroprotection, as ERRs are expressed in the brain and linked with anti-aging pathways.
    • Optimizing endurance and muscle function research in preclinical settings.

    2. Comparative Insights

    3. Data-Driven Outcomes

    • SLU-PP-332 increased mitochondrial respiration in C2C12 myocytes by >30% compared to controls.
    • In murine models, SLU-PP-332 treatment improved endurance exercise capacity by up to 25% and significantly reduced fat mass accumulation.
    • Gene expression analysis showed a 2- to 3-fold induction of Pdk4 and mitochondrial biogenesis markers following treatment.

    Troubleshooting and Optimization Tips

    • Compound Handling: Minimize freeze-thaw cycles; prepare single-use aliquots. If insolubility occurs, gently warm or apply ultrasonic treatment (especially for ethanol stocks).
    • Dosing Precision: Leverage a slu-pp-332 dosage calculator or consult the “slu pp 332 dosage pdf” for accurate conversions from in vitro concentrations to animal model dosing.
    • Vehicle Effects: Ensure DMSO or ethanol vehicle controls are included to account for solvent effects in both cell and animal studies.
    • Assay Sensitivity: For mitochondrial assays, confirm instrument calibration and use positive controls (e.g., AICAR or PGC-1α agonists) for benchmarking.
    • Stability Checks: Verify solution clarity before use; discard if precipitation or discoloration is observed.
    • Biological Variability: In primary cells or in vivo models, anticipate inter-sample variability—standardize dosing time and nutritional status to reduce confounders.

    Future Outlook: SLU-PP-332 in Translational and Clinical Research

    SLU-PP-332’s unique profile as a pan-ERR agonist underpins its translational potential for metabolic, neurodegenerative, and aging-related disorders. Its oral bioavailability and robust efficacy in preclinical models position it as a promising candidate for non-invasive peptide therapy research. Ongoing studies are further clarifying long-term safety and optimizing the structure for clinical use (Mahale et al., 2024).

    Key research frontiers include:

    • Refining slu-pp-332 dosage regimens for chronic metabolic disease models.
    • Expanding neuroprotection studies and anti-aging applications.
    • Developing advanced slu-pp-332 dosage calculators and open-access protocols for standardized research.
    • Comparative studies with other mitochondrial biogenesis activators to delineate unique benefits and limitations.

    For those seeking to buy this innovative compound, SLU-PP-332 for sale is available through APExBIO, ensuring quality and reliability for advanced research applications.

    Keywords: SLU-PP-332, ERRα ERRβ ERRγ agonist, estrogen-related receptor agonist, mitochondrial biogenesis activator, enhancement of mitochondrial function, cellular respiration regulator, PGC-1α pathway activation, nuclear receptor signaling, slu-pp-332 for sale, slupp332, slu-pp-332 dosage, slu pp 332 dosage, slu-pp-332 dosage calculator, slupp332 peptide, slu pp 332 dosage of 250mcg per day, slu pp 332 for sale, slu-pp-332 dosage per day pdf, slu-pp 332, slupp peptide, slu-pp-332 250mcg, slu pp, slu pp 332 buy online, slu-pp-322, slupp 332, slu pp 332 dosage calculator, slu pp 32, slu pp 332 for sale usa, slu pp 332 dosage pdf, slu-pp-332 for sale usa, slu pp 332 dosage chart, slu pp 322, slu pp 332 amino asylum, what is slu-pp-332, slu-pp-332 peptide benefits, what is slu pp 332